Odyssey Therapeutics, Inc.
ODTX Nasdaq
SEC CIK 1882782
Follow Odyssey Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$53.1M
−49.6% vs same quarter last year
EPS, diluted
−$1.10
+85.9% vs same quarter last year
Operating cash flow
−$41.5M
−32.9% vs same quarter last year
Source: SEC XBRL filings · latest filing